Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us
Conference Highlights
American Society of Hematology (ASH)
ASH 2020 – Multiple Myeloma
ASH 2020 – Multiple Myeloma
Selinexor in Combination with Pomalidomide and Dexamethasone for Treatment of Patients with RRMM
ASH 2020 – Multiple Myeloma
Interim results from the STOMP study show that the combination of selinexor, pomalidomide, and dexamethasone appears to offer relatively high overall response rates and encouraging progression-free survival in heavily pretreated patients with multiple myeloma.
Read More ›
Ciltacabtagene Autoleucel Is a BCMA-Directed Chimeric Antigen Receptor T-Cell Therapy, in RRMM
ASH 2020 – Multiple Myeloma
The preliminary results of the phase 1b/2 CARTITUDE-1 study revealed that early, deep, and durable responses were demonstrated and that a safety profile consistent with prior studies with a single low-dose infusion of ciltacabtagene autoleucel in heavily pretreated patients with RRMM was observed.
Read More ›
AMG 701, a Bispecific T-Cell Engager Molecule, in RRMM: A Phase 1 First-in-Human Study
ASH 2020 – Multiple Myeloma
Results from a first-in-human study of AMG 701, an anti-BCMA BiTE molecule, showed an acceptable safety profile, promising efficacy, and a favorable pharmacokinetic profile in heavily pretreated patients with RRMM, thereby supporting ongoing evaluation.
Read More ›
Open-Label, Phase 1b/2, Dose-Escalation Study of a Novel Agent in Patients with RRMM (STOMP)
ASH 2020 – Multiple Myeloma
The combination of selinexor, pomalidomide, and dexamethasone is efficacious, durable and safe in patients with RRMM.
Read More ›
Phase 2 GRIFFIN Study Update: Daratumumab + Lenalidomide, Bortezomib, and Dexamethasone in Transplant-Eligible NDMM
ASH 2020 – Multiple Myeloma
Adding daratumumab to lenalidomide, bortezomib, and dexamethasone induction and consolidation, followed by maintenance with lenalidomide ± daratumumab for transplant-eligible patients with NDMM elicits deep and improving responses, with no additional safety concerns upon longer follow-up.
Read More ›
Isatuximab for Patients with Previously Treated AL Amyloidosis
ASH 2020 – Multiple Myeloma
Results from a phase 2 study of isatuximab in previously treated patients with amyloid light-chain (AL) amyloidosis showed encouraging efficacy and a good safety profile.
Read More ›
A Dose-Finding Study of Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone for RRMM
ASH 2020 – Multiple Myeloma
Although promising efficacy and acceptable toxicity were reported for belantamab mafodotin + pomalidomide + dexamethasone in patients with RRMM, the high rate of dose holds at the 2.5-mg/kg level warranted examination of alternative dosing schedules.
Read More ›
APOLLO: Combination of Daratumumab + Pomalidomide and Dexamethasone versus Pomalidomide and Dexamethasone Alone in Patients with RRMM
ASH 2020 – Multiple Myeloma
Daratumumab + pomalidomide and dexamethasone reduced the risk for disease progression and death without additional safety signals versus pomalidomide and dexamethasone alone for patients with RRMM who had received ≥1 prior lines of therapy, including lenalidomide and a proteasome inhibitor.
Read More ›
ANCHOR: Melflufen plus Dexamethasone and Daratumumab or Bortezomib in RRMM Refractory to an Immunomodulatory Drug and/or a Proteasome Inhibitor
ASH 2020 – Multiple Myeloma
The updated efficacy and safety data from the ANCHOR study of melflufen plus dexamethasone and daratumumab or bortezomib in patients with RRMM demonstrated encouraging efficacy that was well-tolerated.
Read More ›
VRD Consolidation Followed by Lenalidomide Maintenance versus Maintenance Alone in Transplant-Eligible Patients with NDMM
ASH 2020 – Multiple Myeloma
Consolidation treatment with bortezomib + lenalidomide + dexamethasone (VRD) followed by lenalidomide maintenance proved superior to lenalidomide maintenance alone in progression-free survival and myeloma response among transplant-eligible patients with NDMM.
Read More ›
Page 3 of 3
1
2
3
Conference Correspondent Coverage is Brought to You by the Publishers of:
Learn more about our family of publications.
View Our Publications
Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us